CITIUS PHARMACEUTICALS INC (CTXR)
US17322U2078 - Common Stock
Overall CTXR gets a fundamental rating of 3 out of 10. We evaluated CTXR against 194 industry peers in the Pharmaceuticals industry. While CTXR has a great health rating, there are worries on its profitability. CTXR is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CTXR has reported negative net income.
In the past year CTXR has reported a negative cash flow from operations.
In the past 5 years CTXR always reported negative net income.
CTXR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of CTXR (-40.96%) is comparable to the rest of the industry.
CTXR has a Return On Equity (-46.41%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.96% | ||
| ROE | -46.41% | ||
| ROIC | N/A |
ROA(3y)-26.41%
ROA(5y)-32.34%
ROE(3y)-29.45%
ROE(5y)-39.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTXR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CTXR has more shares outstanding than it did 1 year ago.
CTXR has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CTXR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -0.73, we must say that CTXR is in the distress zone and has some risk of bankruptcy.
CTXR has a Altman-Z score (-0.73) which is in line with its industry peers.
CTXR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.73 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CTXR has a Current Ratio of 6.75. This indicates that CTXR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.75, CTXR is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
A Quick Ratio of 6.75 indicates that CTXR has no problem at all paying its short term obligations.
CTXR has a Quick ratio of 6.75. This is in the better half of the industry: CTXR outperforms 75.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.75 | ||
| Quick Ratio | 6.75 |
3. Growth
3.1 Past
The earnings per share for CTXR have decreased strongly by -22.13% in the last year.
EPS 1Y (TTM)-22.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
CTXR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.80% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25%
EPS Next 2Y78.54%
EPS Next 3Y88.99%
EPS Next 5Y62.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CTXR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 1.65, the valuation of CTXR can be described as very cheap.
Based on the Price/Forward Earnings ratio, CTXR is valued cheaper than 99.48% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.56. CTXR is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.65 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CTXR's earnings are expected to grow with 88.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.54%
EPS Next 3Y88.99%
5. Dividend
5.1 Amount
No dividends for CTXR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CITIUS PHARMACEUTICALS INC
NASDAQ:CTXR (11/15/2024, 9:58:58 AM)
0.3203
-0.01 (-2.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap57.89M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.65 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.96% | ||
| ROE | -46.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.75 | ||
| Quick Ratio | 6.75 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-22.13%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y